Granules India has entered into an agreement with Hubei Biocause Heilen Pharmaceutical Co., Joint Venture Partner for sale of 33,000,000 equity shares of 1 RMB each fully paid-up held by the Company in overseas JV company, Granules-Biocause Pharmaceutical Co. situated in China for a consideration of RMB 109 million. Conclusion of this transaction is subject to fulfilment of certain closing conditions as well as applicable regulatory approvals.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
